Annual Report of Activities CNC 2008 - Center for Neuroscience and ...

ResearchOngoing StudiesBioavailability/Bioequivalence StudiesExecution of an open, randomized and crossed‐over study on the bioequivalence between coated tabletscontaining 30 mg of deflazacort from two different pharmaceutical laboratoriesExecution of an open, randomized and crossed‐over study on the bioequivalence between coated tabletscontaining 6 mg of deflazacort from two different pharmaceutical laboratoriesClinical TrialsA 54‐week, double‐blind, randomized, placebo‐controlled, parallel‐group study to investigate the effects ofrosiglitazone as adjunctive therapy to donepezil on cognition and overall clinical response in APOE e‐stratifiedsubjects with mild to moderate Alzeheimer’s disease (REFLECT‐2)Food‐effect and dosage form proportionality study of esclicarbazepine acetate market formulation in healthysubjectsA randomized, comparative, double‐blind, parallel‐Group, Multicenter, Monotherapy, study of Pregabalin(Lyrica) and Lamotrigine (Lamictal) in patients with newly diagnosed partial seizuresA Pan‐European randomized, parallel group, two‐arm placebo‐controlled, double‐blind multicenter study ofRimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting blood glucosewith or without other comorbiditiesA multicenter, randomized, double blind, parallel‐group placebo and pramipexole controlled study to assessefficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease139Clinical Trial to asses the efficacy of probiotic milkAn open label SLV308 safety extension to study S308.3.003 in early PD patientsA 52‐week open‐label extension study of the long‐term safety and efficacy of rosiglitazone extended‐release (RSGXR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild‐to‐moderate alzheimer´sdisease (REFLECT‐4)A randomized, double‐blind, parallel group, multi‐center, comparative, flexible dose trial of pregabalin versusgabapentin as adjunctive therapy in subjects with partial seizures.A Multi‐Center, Placebo‐Controlled, Double‐Blind Trial To Examine the Safety and Efficacy of ACP‐103 in theTreatment of Phychosis in Parkinson’s DiseaseA Multi‐Center, Open‐Label Extension Study to Examine the Safety and Tolerability of ACP‐103 in the Treatmentof Psychosis in Parkinson’s DiseaseA Historical‐controlled, Multicenter, Double‐blind, Randomized Trial to Assess the Efficacy and Safety ofConversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial‐onset SeizuresA Multicenter, Open‐label Extension Trial to Assess the Long‐term Use of Lacosamide Monotherapy and Safetyof Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial‐onset SeizuresDrug Dosages StudiesDosage of metformin in plasma samples from the BIA‐2093‐125 clinical trialDosage of gliclazide in plasma samples from the BIA‐2093‐126 clinical trialDosage of antidiabetics in plasma samples from the BIA‐2093‐206 clinical trial